Development of chemotherapy-induced neuropathic pain (CINP) compromises the use of chemotherapy and greatly impacts thousands of lives. Unfortunately, there are no Food and Drug Administration-approved drugs to prevent or treat CINP. Neuropathological changes within CNS, including neuroinflammation and increased neuronal excitability, are driven by alterations in neuro-glia communication; but, the molecular signaling pathways remain largely unexplored. Adenosine is a potent neuroprotective purine nucleoside released to counteract the consequences of these neuropathological changes. Adenosine signaling at its adenosine receptors (ARs) is dictated by adenosine kinase (ADK) in astrocytes, which provides a cellular sink for the removal of extracellular adenosine. We now demonstrate that chemotherapy (oxaliplatin) in rodents caused ADK overexpression in reactive astrocytes and reduced adenosine signaling at the A 3 AR subtype (A 3 AR) within the spinal cord. Dysregulation of ADK and A 3 AR signaling was associated with increased proinflammatory and neuroexcitatory interleukin-1b expression and activation of nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome, but not putative oxaliplatin-associated GSK3b transcriptional regulation. Intrathecal administration of the highly selective A 3 AR agonist MRS5698 attenuated IL-1b production and increased the expression of potent anti-inflammatory and neuroprotective IL-10. The effects of MRS5698 were blocked by attenuating IL-10 signaling in rats with intrathecal neutralizing IL-10 antibody and in IL-10 2/2 knockout mice. These findings provide new molecular insights implicating astrocyte-based ADK-adenosine axis and nucleotide-binding oligomerization domain-like receptor protein 3 in the development of CINP and IL-10 in the mechanism of action of A 3 AR agonists. These findings strengthen the pharmacological rationale for clinical evaluation of A 3 AR agonists already in advanced clinical trials as anticancer agents as an adjunct to chemotherapy.
Introduction
The development of chemotherapy-induced neuropathic pain (CINP) is a major dose-limiting neurotoxicity created by widely used chemotherapeutic agents, 5 including the platinum-based drug, oxaliplatin. Chemotherapy-induced neuropathic pain can occur in up to 60% of patients receiving oxaliplatin, which is used as a first-line chemotherapeutic for treatment of colorectal cancer. 5 Chemotherapy-induced neuropathic pain can linger for years and greatly impacts a patient's quality of life due to inadequate pain management with currently available analgesics. 11 Finding novel therapies for these patients are hampered by our poor understanding of the cellular and molecular mechanisms involved. Peripheral neuropathological changes in response to chemotherapeutics are considered the provocative processes for the development of CINP 50 ; however, neuropathological changes within the CNS are critical for establishing the chronic pain state. 50 We have recently reported that highly selective A 3 adenosine receptor (AR) agonists block and reverse CINP, 21, 24 suggesting that chemotherapy causes the dysregulation of adenosine signaling at this receptor subtype. However, the underlying mechanisms that drive these pathways and the molecular pathways engaged by A 3 AR agonism remain to be defined.
Astrocytes in the spinal cord are emerging as the predominant cellular agent in establishing CINP 18 unlike in other types of neuropathic pain where both astrocyte and microglial cell activation contribute to neuropathological processes. 39 The mechanisms initiated in astrocytes responsible for establishing CINP remain elusive. We hypothesized a role for the dysregulation of adenosine kinase (ADK) in spinal cord. In the adult brain, ADK is found primarily in astrocytes where it is the predominant determinate of extracellular adenosine levels. 2, 8, 27 Adenosine kinase establishes an adenosine gradient by converting intracellular adenosine to ATP to remove adenosine from the extracellular space down its concentration gradient through equilibrative nucleotide transporters. 2, 4, 6 Adenosine kinase expression increases in astrocytes on their activation and contributes to a number of neuropathologies. 2, 25, 46 Increasing ADK expression compromises the beneficial effects of adenosinergic signaling by creating deficits in extracellular adenosine levels 2, 25, 46 and shifting purinergic signaling towards ATP and P2Y and P2X receptor-driven neuroinflammatory processes, which include activating the nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome-IL-1b pathway. 13, 19, 49 Conversely, maintaining adequate extracellular adenosine provides protection to neurons and glial cells during stress through its signaling at its 4 G protein-coupled ARs (A 1 AR, A 2A AR, A 2B AR, and A 3 AR). 4 A 3 AR is expressed throughout the CNS in neurons and astrocytes and its activation with selective A 3 AR agonists has been found to reduce neuronal excitability and attenuate astrocyte activation during neuroinflammation. 23 Here, we reveal for the first time that oxaliplatin causes the dysregulation of extracellular adenosine signaling at the A 3 AR in the spinal cord by inducing ADK expression in astrocytes and engaging NLRP3-IL-1b neuroinflammation. Restoring A 3 AR signaling in the spinal cord by inhibiting ADK or activating A 3 AR with intrathecal (i.th.) selective A 3 AR agonists prevented the establishment CINP. The beneficial effects of A 3 AR signaling were associated with a shift in the neuroinflammatory cytokine balance after the attenuation of NLRP3 activation and IL-1b production and the counteractive engagement of IL-10 signaling pathways. Because an A 3 AR agonist shows promise in clinical trials as an anticancer agent, 1 these findings provide compelling support for clinical development of A 3 AR agonists as adjunct to chemotherapeutic agents. 23 Our work addresses a huge unmet medical need while filling major gaps in our understanding of the role of astrocytes in CINP.
Materials and methods

Experimental animals
Male Sprague-Dawley rats (200-250 g starting weight) from Envigo (Harlan) Laboratories (Indianapolis, IN; Frederick, MD breeding colony) were housed 1 to 4 per cage in a controlled environment (12-hour light/dark cycle) with food and water available ad libitum. Male wild-type C57BL/6 or IL-10 2/2 mice (B6.129P2-Il10 tm1Cgn /J; 7 weeks old; age-and sex-matched) were purchased from Jackson Laboratory (Bar Harbor, ME) and housed 5 to 10 per cage in a controlled environment (12- November 12, 2015) . All experiments were conducted with the experimenters blinded to treatment conditions. Animals were randomly placed in groups. 
Test compounds
MRS5698 ((1S,2R,3S,4R,5S)-4-(6-((3-chlorobenzyl)amino)-2-((3,4- difluorophenyl) ethynyl)-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo
Chemotherapy-induced neuropathic pain
Oxaliplatin (Oncology Supply; Dothan, AL) or its vehicle (5% dextrose) was administered as an i.p. injection in rats on 5 consecutive days (D0-4) for a final cumulative dose of 10 mg/kg. 24 This low dose paradigm does not cause kidney injury, as previously reported. In mice, oxaliplatin (3 mg/kg) or its vehicle (5% dextrose) was administered i.p. for 5 consecutive days (D0-4) and then again D10 to 14 for a total cumulative dose of 30 mg/kg. 47 
Intrathecal catheterization and injection
Rats were catheterized intrathecally using the L5/L6 lumbar approach described previously by our group. 32 After anesthesia with isoflurane, a guide cannula (20G) was passed between lumbar vertebrae 5 and 6 into the i.th. space. A PE-10 catheter was positioned 3 cm beyond the tip of the cannula near the lumbar enlargement. To prevent displacement of the catheter, the tubing was tunneled subcutaneously to the occipital region through a small skin incision and secured with 5-0 silk sutures. The catheter was flushed with sterile saline and heat-sealed. Animals received Rimadyl (5 mg/kg; subcutaneously) and were allowed to recover on a heating pad and then were singlehoused. Intrathecal injections (5 or 10 mL) were administered using a 25-or 50-mL Hamilton syringe followed by a 10-mL sterile saline flush. Animals were excluded if they did not have patent catheters, showed signs of infection or adverse reactions to the surgery (ie, abnormal posture, grooming, locomotor behaviors, abnormal hair coat, piloerection, ocular porphyrin discharge, and loss of body weight), or exhibited abnormal pain behaviors before the start of chemotherapy and drug treatment on D0. ). The development of mechano-allodynia is evidenced by a significant (P , 0.05) reduction in mechanical mean absolute PWT (g) at forces that failed to elicit withdrawal responses before chemotherapeutic treatment (D0).
Mechano-hyperalgesia
Paw withdrawal thresholds (g) were measured using the Randall and Selitto 42 paw pressure test using a Ugo-Basile analgesiometer (Monvalle, Italy, model 37215) that applies a linearly increasing mechanical force to the dorsum of the rat's hind paw. The nociceptive threshold was defined as the force (g) at which the rat withdrew its paw (cut off set at 250 g). Chemotherapeutic treatment results in bilateral allodynia and hyperalgesia with no differences between left and right PWTs (g) at any time point in any group; thus, the values from both paws were averaged. Animals receiving chemotherapeutic agents in the presence or absence of the experimental test substances tested did not display signs of any toxicities: that is, they exhibited normal posture, grooming, locomotor behavior, hair coat was normal, no signs of piloerection or ocular porphyrin discharge, and gained body weight normally and comparable with vehicle-treated rats.
Western blot
Western blot analyses were performed as previously described with slight modifications. 32 Dorsal lumbar spinal cord samples were homogenized and protein concentrations were determined using bicinchoninic acid protein assay (Thermo Fisher Scientific, Waltham, MA). Proteins were denatured in Laemmli buffer and boiled for 5 minutes. The proteins (20-40 mg) were resolved using sodium dodecyl sulphate-polyacrylamide gel electrophoresis and transferred to nitrocellulose or polyvinylidene fluoride membranes. Membranes were blocked for 2 hours at room temperature in 5% nonfat dried milk or 1% bovine serum albumin in 1X phosphate buffered saline (PBS), pH 7.4, depending on manufacturer's protocol for antibody and subsequently probed with specific antibodies: anti-pGSK3b (1:1000; Cell Signaling Tech, Danvers, MA, #5558), anti-GSK3b (1:1000; Cell Signaling, #12456), anti-ADK (1:500; Thermo Fisher Scientific, Italy, #PA5-27399), anti-NLRP3 (1:400; Santa Cruz Biotechnology, Santa Cruz, CA, #sc-66846), anti-GFAP (1:1000; Dako, Santa Clara, CA #Z0334), or anti-caspase 1 (1:500; Santa Cruz Biotechnology, #sc-1597) in 1X PBS, 2.5% nonfat dried milk, or 0.1% bovine serum albumin and 0.1% Tween-20 at 4˚C overnight. The bound antibodies were then visualized after incubation with anti-rabbit IgG DyLight 488 (1:1000; Thermo Fisher Scientific), peroxidaseconjugated bovine anti-mouse IgG secondary antibody (1:3000; Jackson ImmunoResearch, West Grove, PA), peroxidaseconjugated goat anti-rabbit IgG (1:3000; Jackson ImmunoResearch), or donkey anti-mouse IgG DyLight 650 (1:1000; Thermo Fisher Scientific) for 1 hour at room temperature. Peroxidase-conjugated antibodies were visualized using enhanced chemiluminescence (Bio-Rad, Hercules, CA). Chemiluminescence and fluorescent-tagged antibody signal were documented using Chemidoc XRS1 documentation system and Image Lab software (Bio-Rad, Hercules, CA) and quantified for band densitometry. Each membrane was then probed for b-actin (1:5000; Sigma-Aldrich, St. Louis, MO) for use as endogenous loading controls.
Immunofluorescence and image analysis
Immunofluorescence was performed using modifications of previously reported methods. 31 After behavioral measurements, rats were killed according to SLU IACUC regulations. The lower lumbar enlargement of the spinal cord (L4-L6) was harvested, transferred to OCT, and frozen in an isopropanol and dry ice bath. Transverse sections (20 mm) were cut using a cryostat, collected on gelatin-coated glass microscope slides, and stored at 220˚C. Spinal cord sections were fixed in 10% buffered neutral formalin (10 minutes), blocked (10% normal goat serum, 2% bovine serum albumin, and 0.2% Triton-X100 in PBS, for 1 hour), and then immunolabeled using an 18-hour incubation (4˚C) with rabbit polyclonal anti-ADK (1:100; Thermo Fisher) and mouse monoclonal anti-NeuN (1:1000; EMD Millipore, Burlington, MA), antiglial fibrillary acidic protein (GFAP) (1:1000; Sigma-Aldrich), or anti-CD11b antibody (OX42, 1:200; Millipore). After a series of PBS rinses, sections were incubated for 2 hours with a goat antirabbit Alexa Fluor 568 conjugated (1:250; Invitrogen, Carlsbad, CA) and anti-mouse Alexa Fluor 488 conjugated antibody (1:250; Invitrogen). The coverslips were mounted with Fluorogel II containing DAPI [4,6-Diamidino-2-phenylindole, dihydrochloride] to label nuclei (Electron Microscopy Sciences, Hatfield, PA) and immunolabeled spinal cord sections observed with an Olympus FV1000 MPE confocal microscope (multiline argon lasers with excitation at 405, 488, and 543 nm) using a 10X objective (UPLSAPO; 0.4 NA) for regional fluorescence intensity image analysis. Images were acquired within the dynamic range of the microscope (ie, no pixel intensity values of 0 or 255 in an 8-bit image). Sections treated with isotype controls at equivalent concentrations to primary antibodies yielded only nonspecific background fluorescence. The mean fluorescence intensity in the dorsal horn was determined as previously reported. 15, 22, 24, 31 Image analysis was performed using the NIH freeware program ImageJ (version 1.43). 45 The superficial dorsal horns (laminae I and II) at the L4, L5, and L6 levels (3 sections per animal; n 5 4 animals per group) were outlined on images bilaterally using the ImageJ region of interest tool. The superficial dorsal horn was determined and confirmed using cresyl violet-stained sections of adjacent sections and an atlas. 41 There were no significant differences bilaterally; so, mean fluorescence intensity was calculated as a combined value and reported as fold-change compared with the vehicle group.
Colocalization studies were performed for ADK expression with astrocytes (anti-GFAP), microglia (anti-CD11b, OX-42), and neurons (anti-NeuN) using analysis of 3 confocal Z-stacks from the medial, middle, and lateral portions of the lumbar superficial dorsal horn (L4) in oxaliplatin and vehicle-treated rats. Higher magnification colocalization studies were performed using an Olympus FV1000 confocal microscope (multiline argon lasers with excitation at 405, 488, and 543 nm) with 60X oil-immersion objective (1.42 NA) and 2.4X zoom to provide 0.1-mm pixel dimensions in the X-Y plane and the pinhole set at 1 Airy unit. Zstack images (3 Z-stacks per animal) were obtained using sequential scanning at a 0.2 mm Z-step with a minimum of 50 total steps (10 mm). The images were acquired within the dynamic range of the microscope (ie, no pixel intensity values of 0 or 255 in an 8-bit image). Z stacks underwent deconvolution with the deconvolution wizard tool using Huygens Essential (Scientific Volume Imaging v14.10) and were analyzed for 3D colocalization. Manders overlap coefficient (M) was used to assess ADK colocalization with NeuN, GFAP, or OX42. Manders 36 coefficient was calculated to compare the proportion of NeuN-, GFAP-, or OX42-labeled voxels that are also labeled for ADK. In addition to colocalization, 3D-rendered images were analyzed in ImageJ using the 3D viewer plugin to count ADK-positive (ADK 1 ) cell profiles that are coexpressed with NeuN-, GFAP-, or OX42-positive (NeuN 1 , GFAP 1 , or OX42 1 ) cells as previously described. 46 A positive cell profile was defined as one that was labeled with ADK or cell markers with a DAPI-labeled nucleus. Total ADK 1 cell profiles and those ADK 1 cell profiles that colocalized with NeuN 1 , GFAP 1 , or OX42 1 cell profiles were counted and reported as a percentage (number of coexpressed ADK 1 cells:total ADK 1 cells and normalized to total DAPI nuclei). Images are shown at one level of the z stack and in a 3D-rendered Z stack in maximum intensity projection mode in XYZ with orthogonal ZY and YZ slices (Huygens Essential v.14.10).
Cytokine determination
The levels of cytokines within the dorsal horn of the lumbar spinal cord were assessed using a commercially available enzymelinked immunospecific assay kit (Thermo Fisher Scientific).
Statistical analyses
Data are expressed as mean 6 SD for n animals. Data were analyzed using Student t test or 2-tailed, 2-way repeatedmeasures, or 1-way analysis of variance with Holms-Sidak post hoc comparisons. Significant differences were defined as P , 0.05. All statistical analyses were performed using GraphPad Prism (v6.04; GraphPad Software, Inc).
Results
Adenosine kinase expression in the spinal cord is increased with oxaliplatin treatment
Using an established model of oxaliplatin-induced neuropathic pain, 20, 24, 53 we found that the development of mechanoallodynia and mechano-hyperalgesia (neuropathic pain) (Figs. 1A and B) and astrocyte activation (increased expression of GFAP; Fig. 1C) were associated with time-dependent increases in ADK expression in the dorsal horn of the spinal cord (DH-SC; Fig. 1D ). Immunofluorescence analyses of the superficial DH-SC from oxaliplatin-treated rats demonstrated similar increases in ADK expression on D25 (Figs. 1E-G) . Colocalization analyses revealed that ADK was expressed in both astrocytes (GFAP 1 ; Fig. 2 2, 8, 27 Thus, the increased ADK expression observed in the cytoplasm of astrocytes could be sufficient to suppress spinal extracellular adenosine and contribute to oxaliplatininduced neuropathic pain. 
Increased astrocyte adenosine kinase through deficient A3AR signaling promotes neuropathic pain
To test the functional significance of such increased ADK expression, rats were administered i.th. injections of ABT-702 (30 nmol/day) during oxaliplatin treatment. ABT-702 is a potent (IC 50 5 1.7 nM) and highly selective non-nucleoside ADK inhibitor. 28 When compared with its vehicle, ABT-702 attenuated mechano-allodynia and mechano-hyperalgesia (Figs. 1A and B) . Moreover, the beneficial effects of ABT-702 were blocked by daily i.th. injections of the A 3 AR antagonist, MRS1523 32 ( Figs. 1A and  B) . This suggested that oxaliplatin-induced ADK expression depressed beneficial A 3 AR signaling. Indeed, when i.th. injections of the highly selective A 3 AR agonist MRS5698 (3 nmol/day) 32 were given to rats concurrently with oxaliplatin treatment, the development of mechano-allodynia was blocked through day 25 (Figs. 4A and B) .
Restoring deficient adenosine signaling attenuates oxaliplatin-induced NLRP3-IL-1b neuroinflammation
Activation of astrocytes and increased formation of IL-1b are significant contributors to the neuroinflammatory processes that promote CINP. 21, 22, 24, 44 Supplementing A 3 AR signaling with i.th. injection of MRS5698 during oxaliplatin treatment significantly reduced IL-1b levels in the spinal cord (Fig. 4C) . To investigate the potential mechanisms through which supplemental A 3 AR signaling attenuated neuroinflammation, we examined 2 well-known pathways that provide tight regulation of the neuroinflammatory balance and are critical in the regulation of pro-and anti-inflammatory cytokines: GSK3b and NLRP3-inflammasome. 35, 38 GSK3b activity has recently been linked to the development of CINP after paclitaxel. 16 GSK3b is a constitutively active serine and threonine protein kinase and its activity is attenuated primarily through AKT-mediated phosphorylation of serine-9. 26 However, as shown in Figure 4E , the levels of GSK3b serine-9 phosphorylation (p-GSK3b) and total GSK3b in spinal cord dorsal horn at time of peak neuropathic pain were similar in oxaliplatin-and vehicle-treated rats (Fig. 4E) . Moreover, i.th. injection of the GSK3b inhibitor, AR-A014418 (100 ng/day), 51 did not block oxaliplatin-induced neuropathic pain (Fig. 4F) .
By contrast, we found significant activation of the NLRP3 inflammasome. Nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) is an intracellular signaling molecule that senses many endogenous and pathogen-derived danger signals. 49 On activation, NLRP3 forms the inflammasome complex by binding and stimulating the autoactivation of the cysteine protease caspase-1 that catalyzes the cleavage of pro-IL-1b to the active form, IL-1b. 49 Results in Figures 4G and H demonstrate significantly increased expression of the NLRP3 subunit and maturation of caspase 1 (p20) in animals treated with oxaliplatin when compared with vehicle groups. Blocking NLRP3-inflammasome activity with daily i.th. injections of the potent, selective, small molecule NLRP3 inhibitor, MCC950 (5 mmol/day, a dose previously shown not to inhibit other inflammasomes 7 ), significantly attenuated oxaliplatin-induced neuropathic pain (Figs. 4A and B) . MCC950 inhibits NLRP3-dependent oligomerization of apoptosis-associated speck-like protein containing Collectively, these results suggest that oxaliplatin induces the activation of NLRP3 and not GSK3b during the development of chronic pain. Moreover, supplementing A 3 AR signaling in rats with i.th. MRS5698 during oxaliplatin treatment significantly reduced NLRP3 protein expression and caspase 1 maturation in the DH-SC compared with those receiving vehicle (Figs. 4G and H). These data suggest that A 3 AR attenuates neuroinflammation by interfering with the activation of NLRP3 signaling.
Restoring deficient adenosine signaling promotes IL-10 signaling
The inhibitory actions of MRS5698 on IL-1b were associated with significant increases in the levels of IL-10, a potent neuroprotective and anti-inflammatory cytokine, 30 in the DH-SC (Fig.  4D) , suggesting that the effects of A 3 AR agonists could be driven through IL-10. In support, MRS5698 lost its ability to block oxaliplatin-induced neuropathic pain in mice with genetic ablation of IL-10 when compared with their sex-and age-matched wild-type controls (Figs. 5A and B) or in rats when a neutralizing anti-IL-10 antibody was coinjected i.th. (aIL-10; 0.2 mg/day) (Figs. 5C and D) . Intrathecal aIL-10 also blocked the beneficial effects of ABT-702 on neuropathic pain (Figs. 6A and B) . Moreover, the administration of the neutralizing anti-IL-10 antibody prevented the attenuation NLRP3 activation and IL-1b production in the rat DH-SC by MRS5698 (Figs. 4C, G, and H) and restored IL10 levels to those found in oxaliplatin-treated animals, suggesting that aIL-10 prevented the ability of A 3 AR agonists to attenuate IL-1b-driven neuroinflammation. Indeed, mechanohypersensitivities were blocked in rats treated i.th. with interleukin-1 receptor antagonist (IL-1RA; 100 mg/day; i.th.) in the presence of MRS5698 and aIL-10 (Fig. 5D ).
Discussion
Our studies provide the first molecular insights into adenosinergic mechanisms that contribute to the development of pain associated with oxaliplatin regimens. Our findings suggest that oxaliplatin treatment significantly increases the expression of ADK within astrocytes of the superficial DH-SC where pain is actively processed and modulated. This increase in ADK is sufficient to promote the development of neuropathic pain because its inhibition during oxaliplatin treatment blocks mechanoallodynia and mechano-hyperalgesia from ever developing. Moreover, our findings that A 3 AR antagonists block the beneficial effects of ADK inhibition or that supplementing A 3 AR signaling using A 3 AR agonist suggests that oxaliplatininduced ADK activity creates deficiencies in protective A 3 AR signaling. Collectively, these data allow us to propose a novel mechanistic model whereby oxaliplatin spurs astrocytic ADK activity in the DH-SC to reduce extracellular adenosine that otherwise would provide protection through A 3 AR signaling against maladaptive changes in DH-SC.
Upregulation of ADK in the astrocytes and the dysregulation of extracellular adenosine signaling is a common feature in numerous pathologies within the CNS, including epilepsy, traumatic brain injury, stroke, and cognitive impairment.
2 Nuclear and cytoplasmic isoforms of ADK have been described in cells. 2, 27, 46 The expression of these 2 isoforms is transcriptionally regulated by distinct mechanisms that have been suggested to be associated with their distinct physiological functions. 2, 8 The ADK isoform sequestered within the nucleus is often associated with regulation of the intracellular levels of adenosine, 2,27 whereas the ADK sequestered in the cytoplasm offers tight regulation of extracellular adenosine levels. 2 Within the adult brain, ADK expression is predominantly located in astrocytes and largely composed of cytoplasmic ADK. 2, 46 Its overexpression is linked to increased dysregulation of synaptic signaling and inflammation through the loss of AR signaling. 2, 9 Thus, it is likely that the increase in cytoplasmic ADK in astrocytes that is largely responsible for the effects observed in our model. However, we also detected astrocyte and neuronal expression of nuclear ADK, which has been observed in neurons of CNS regions known to undergo greater levels of neuroplasticity (granular cell layer neurons of the dentate gyrus, olfactory neurons, etc). 2, 17, 46 Nuclear ADK is used in intracellular processes such as the DNA transmethylation pathway. 2, 8, 17, 27, 46, 52 DNA methylation is a dynamic epigenetic process that can occur in postmitotic neurons 12, 33, 34, 52 wherein intracellular adenosine is created as a hydrolysis product of S-adenosyl-homocysteine; nuclear localized ADK salvages this major source of intracellular adenosine to maintain methylation. 3 Previous work in epilepsy demonstrated that in addition to astrocyte-dependent processes, increased nuclear ADK levels can also result in adenosine-reversible DNA hypermethylation in neurons to promote such pathophysiological events, such as enhanced synaptic plasticity. 52 Currently, it is unclear what, if any, role nuclear ADK may play in CINP. We are currently examining the functional role of enhanced spinal dorsal horn ADK levels in epigenetic modifications including DNA methylation on gene expression during pain.
Our findings reveal that among the maladaptive responses in the DH-SC provoked by oxaliplatin, the dysregulation of ADK www.painjournalonline.com 1031 expression in astrocytes and consequent reductions in extracellular adenosine signaling are significant contributors to oxaliplatin-induced spinal neuroinflammation through activation of NLRP3-IL-1b neuroinflammation. IL-1b contributes to neuronal excitability and central sensitization through several mechanisms 43 including dampening the release of anti-inflammatory and neuroprotective molecules, such as interleukin-1 receptor antagonist (IL1RA) and IL-10, which are typically produced in an attempt to counterbalance and attenuate an exaggerated neuroinflammatory response. 29 By contrast, the restoration of adenosine signaling with a selective A 3 AR agonist blocked NLRP3-IL-1b pathways and prevented neuropathic pain from ever developing. Moreover, our findings using both pharmacological and genetic approaches to block IL-10 signaling suggest that A 3 AR agonists disengage the inhibition on IL-10 production and/or signaling during the development of CINP. This is anticipated to allow IL-10 to engage its powerful antiinflammatory and neuroprotective signaling pathways, which include attenuating the activation of NLRP-IL-1b pathways. 30 These results underscore the dependency of IL-10 downstream of A 3 AR activation, and support findings in unrelated pathologies. For example, beneficial effects exerted by A 3 AR agonists in a model of experimental autoimmune uveitis were also found to be driven by IL-10. 14 In addition to NLRP3 inflammasome, our examination of the GSK3b pathway indicates that its role in CINP is nominal, despite a reported link between A 3 AR agonism and the GSK3b pathway ischemia/reperfusion injury in cardiomyocytes.
14 However, this may depend more on which chemotherapeutic is used than on A 3 AR agonism. GSK3b appears to be engaged with paclitaxel, 16 but not with oxaliplatin (our study and another). 37 These findings may suggest underlying differences in the mechanisms engaged by chemotherapeutics during the development of CINP and how the beneficial effects of A 3 AR agonism are exerted with different chemotherapeutics. These differences may have significant importance to future development of CINP therapies and require further study.
In summary, our results unravel a previously unrecognized link whereby chemotherapy-induced upregulation of ADK in astrocytes causes neuropathic pain by disrupting adenosine signaling at the A 3 AR and engaging NLRP3-IL-1b neuroinflammation. Chemotherapy-induced alteration of this molecular axis is rescued by A 3 AR agonists. These results suggest that A 3 AR agonists and NLRP3 inflammasome inhibitors offer a potential Figure 5 . Beneficial effects of MRS5698 in CINP depend on IL-10: evidence from a pharmacological and genetic approach. Oxaliplatin-induced mechanoallodynia in IL-10 2/2 and WT control mice to a similar extent. However, MRS5698 (1 mg/kg/day; i.p.) given with oxaliplatin blocked the development of mechanoallodynia in WT (A), but not IL-10 2/2 mice (B). Intrathecal delivery of a neutralizing aIL-10 antibody, but not its nonspecific IgG (0.2 mg/day), given just before i.t. MRS5698 (3 nmol/day) prevented MRS5698's effects (C). Intrathecal IgG or aIL-10 had no effect on behavior in rats treated with vehicle or oxaliplatin (C). Pretreatment with spinal IL-1RA (100 mg/day; i.th.) before aIL-10, abrogated the inhibitory actions of aIL-10 on MRS5698 (D). Results are expressed as mean 6 SD for (A and B: n 5 3/group), (C: Veh 1 aIL-10 or IgG n 5 3/group, Ox 1 aIL-10 or IgG n 5 3/group, Ox 1 MRS5698 1 aIL-10 or IgG n 5 6/group), and (D: n 5 6/ group). Two-way ANOVA with Holms-Sidak comparisons *P , 0.05 compared with D0; †P , 0.05 vs oxaliplatin; #P , 0.05 vs oxaliplatin 1 MRS5698. (-) 5 duration of treatment. ANOVA, analysis of variance; CINP, chemotherapy-induced neuropathic pain; PWT, paw withdrawal threshold; WT, wild-type.
